top of page
About
Team
Science
News
Careers
Latest News
Press Release
Synnovation Therapeutics Announces Second Program to Enter the Clinic: First Patient Dosed in Phase I Trial with SNV4818, a Potential Best-In-Class Pan-Mutant-Selective PI3Kα Inhibitor for the Treatment of Solid Tumors
February 24, 2025
View Press Release
Press Release
Synnovation Therapeutics Announces First Patient Dosed in Phase I Trial with SNV1521,
a PARP1 Selective Inhibitor for the Treatment of Solid Tumors
March 11, 2024
View Press Release
Press Release
Synnovation Therapeutics Launches with $102 Million to Advance Clinical-Stage Pipeline of Precision Therapies Targeting Highly Validated Disease Pathways
January 24, 2024
View Press Release
Article
Exclusive: Reid Huber reunites with former Incyte colleague Wenqing Yao, backs Synnovation with $102M for three trials
Januar
y 24, 2024
View Article
bottom of page